Focused On-demand Library for Beta-1,4-galactosyltransferase 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UBV7

UPID:

B4GT7_HUMAN

Alternative names:

Proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I; UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 7; UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 7; UDP-galactose:beta-xylose beta-1,4-galactosyltransferase; XGPT; XGalT-1; Xylosylprotein 4-beta-galactosyltransferase; Xylosylprotein beta-1,4-galactosyltransferase

Alternative UPACC:

Q9UBV7; B3KN39; Q9UHN2

Background:

Beta-1,4-galactosyltransferase 7, known by alternative names such as Proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I and Xylosylprotein beta-1,4-galactosyltransferase, plays a crucial role in the biosynthesis of the tetrasaccharide linkage region of proteoglycans. This enzyme is particularly vital for the production of small proteoglycans in skin fibroblasts, which are essential components of the extracellular matrix.

Therapeutic significance:

The enzyme's involvement in Ehlers-Danlos syndrome, spondylodysplastic type, 1, a connective tissue disorder characterized by skin hyperextensibility and tissue fragility, underscores its therapeutic significance. Understanding the role of Beta-1,4-galactosyltransferase 7 could open doors to potential therapeutic strategies for this and related disorders.